Search

Vemurafenib

[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. … [A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.

Bezitramide

After cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.

Gentian violet cation

A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.

NV1020

NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.

Procarbazine

An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

UM-171

UM-171 is a pyrimidoindole derivative that is an agonist of ex vivo hematopoietic stem cell expansion and thus supports the expansion of hematopoietic stem cells.[A264868, A264873]

Moxonidine

It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive.

Isoflavone

, type II diabetes mellitus, and breast and prostate cancer [A33099]. … The main soy isoflavones are mostly present in glycosylated forms and include [DB01645], [DB13182], and glycitein, which accounts for approximately 50%, 40%, and 10%, respectively, of the total soybean

2-ethylhexyl benzoate

VK-2809

VK-2809 is under investigation in clinical trial NCT02927184 (Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease).